Aerie Pharmaceuticals, Inc.
322 articles with Aerie Pharmaceuticals, Inc.
-
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
11/22/2022
Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc.
-
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
11/3/2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022.
-
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
9/13/2022
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options.
-
Alcon announced it is buying out Aerie Pharmaceuticals for about $770 million to gain access to the ophthalmic pharma firm's open-angle glaucoma and ocular hypertension treatments.
-
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
8/22/2022
Alcon (SIX/NYSE: ALC), and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”), today announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie.
-
Aerie Pharmaceuticals Announces New Employee Inducement Grant - Aug 15, 2022
8/15/2022
Aerie Pharmaceuticals, Inc. announced that the compensation committee of Aerie Pharmaceutical’s board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.
-
Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
8/4/2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), today reports financial results for the second quarter ended June 30, 2022 and provides its business and pipeline objectives and financial guidance for 2022 and beyond, including its expectation to achieve cash flow break even during 2024.
-
Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease
8/1/2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced that the first participant has been dosed in the Phase 3 registrational “COMET-3” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).
-
Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET
7/28/2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present second quarter 2022 financial results after the market closes Thursday, August 4, 2022.
-
Aerie Pharmaceuticals Announces New Employee Inducement Grant - July 08, 2022
7/8/2022
Aerie Pharmaceuticals, Inc. announced that the compensation committee of Aerie Pharmaceutical’s board of directors granted one new employee an award totaling 16,900 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET
5/25/2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will present at the Jefferies Healthcare Conference.
-
Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease
5/24/2022
Aerie Pharmaceuticals, Inc. today announced that the first participant has been dosed in the Phase 3 registrational “COMET-2” study to evaluate AR-15512 ophthalmic solution as a treatment for the signs and symptoms of dry eye disease (DED).
-
Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update
5/5/2022
Aerie Pharmaceuticals, Inc. reports financial results for the first quarter ended March 31, 2022 and reaffirms the business and pipeline objectives and financial guidance previously reported for 2022.
-
Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET
4/28/2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after the market closes Thursday, May 5, 2022.
-
Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022
4/26/2022
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that fourteen abstracts related to Aerie’s Rhopressa®/netarsudil, AR-15512 in dry eye and “ROCK’Sters” anti-inflammatory programs will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting.
-
Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022
4/20/2022
Aerie Pharmaceuticals, Inc. today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., on April 22 through 26, 2022.
-
Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET
4/6/2022
Aerie Pharmaceuticals, Inc. announced that Raj Kannan, Chief Executive Officer, along with Peter Lang, Chief Financial Officer, and Dr. Gary Sternberg, Chief Medical Officer, will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. Eastern Time.
-
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer
3/18/2022
Aerie Pharmaceuticals, Inc. today announced that Peter F. Lang will join the Company as Chief Financial Officer.
-
Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer
2/24/2022
Aerie Pharmaceuticals, Inc. today announced that Gary Sternberg, M.D., M.B.A., will join the Company as Chief Medical Officer (CMO), effective March 1, 2022.